MarkWide Research

Sale!

Next Generation Sequencing Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: July, 2022
No of Pages: 168
Delivery Format: PDF + Excel

$2,950.00

Report Description

Next-Generation Sequencing Market Overview:

The Next Generation Sequencing Market size was $6,598.62 million in 2020 and is expected to grow to $35,503.66 million in 2030, with an increase of 18.2 per cent from 2021 until 2030. Next-generation sequencing (NGS) is a hugely high-speed sequencing technology that provides scalability, high throughput, and high speed to determine the sequence of nucleotides within the entire genome. DNA pre-sequencing is among the most critical steps of the whole sequencing procedure since it requires sample preparation for sequencing. NGS is gradually becoming used in diagnostic tests, clinical laboratory analysis and disease diagnostics in the health care sector globally. NGS has been extensively used in pharmacogenomics to speed up the discovery of drugs.

The growth of the next-generation sequencing market is primarily driven by the growth of genome mapping applications, growth in the use of next-generation sequencing, an increase in healthcare expenses, and advancements in technology in the field of sequencing platforms. For instance, in 2019, Thermo Fisher Scientific, one of the leaders in world scientific research, introduced the Ion Torrent Genexus System. This next-generation platform delivers the sample to report in one day. Additionally, in 2019, Agilent Technologies, Inc., an American manufacturing and analytical development company introduced Magnis NGS Prep System. This next-generation sequencing library preparation tool is designed to run complex sequencing tests with a button pressing. The fetus’s genetic makeup and structure can be identified through tests based on NGS like non-invasive prenatal testing (NIPT) and the preimplantation genetic test (PGT). The R&D in the field of NGS is rising to new levels due to the increased investments in NGS technology across the globe. The increase in demand for genome mapping programs and the rise in NGS applications enhances the NGS market’s development.

Next-Generation Sequencing Market Segmentation

The market for next-generation sequencing is classified according to application, Product, and end-user location. Based on products, this market can be classified into platforms, consumables, and services. The consumption of consumables is further divided based on consumables used in the preparation of samples and other consumables. The consumables used in sample preparation are further divided into three categories: DNA fragmentation, A-Tailing and size selection library preparation, enrichment of target, and quality control. Through platforms, the market is divided by platforms into HiSeq, MiSeq, Ion Torrent, SOLiD, Pacbio Rs II and Sequel Systems, and other sequencing platforms. By service, it’s divided into data management and sequencing services. Management. These services can be further subdivided into RNA sequencing, exome sequencing, total genomic sequencing, targeted sequencing, chip sequencing, de novo sequencing and methyl sequence. The services for managing data are further divided into NGS Data analysis, NGS data analysis software and workbenches, NGS storage management, cloud computing and storage solutions.

In terms of the core applications, the next-generation sequencing market is classified into biomarkers, diagnostics and reproductive health; cancer customized medicine, agricultural and animal research, and other applications. According to technologies, it can be divided into synthesizing, Ion semiconductor sequences, sequencing via the ligation process, pyrosequencing, single-molecule real-time sequencing and various other technologies. For the end-user, the market is classified into research and academic centres, pharmaceutical and biotechnology firms, hospitals and clinics, and other end-users.

On Application

Regionally, the market is analyzed throughout North America (the U.S., Canada and Mexico), Europe (Germany, France as well as Europe (Germany, France UK, Italy, Spain and the rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, Taiwan and the rest of Asia-Pacific) as well as LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and the rest of LAMEA).

Segment review

Based on the Product being used, the consumables segment has dominated the market until 2020. It is anticipated to remain in this position throughout the forecast timeframe because of the rapid advancements in molecular genetics technology and an increase in demand for innovative pre-sequencing kits and products which perform DNA fragmentation, size selection, target enrichment and others. But, the services sector is expected to experience significant future growth in the market for next-generation sequencing in the forecast timeframe because of the advancements in Technology based on SMRT sequencing and the increase in the use of cloud computing for NGS information storage.

Through Technology

Based on the type of application of biomarkers and cancer, the segment was the most dominant market in the year 2020 and is predicted to maintain this pattern throughout the forecast time frame because of the increasing prevalence of cancer and the advancement of Technology in next-generation sequencing. However, the personalized medicine segment is expected to experience significant NGS market growth in the coming years due to the increase in the demand for treatment with drugs, advancements in R&D within the healthcare sector, and the increasing demand for NGS tests in the pharmaceutical and biotechnological industries.

Based on the end consumer, the academic and medical research centre segment led the market in 2020 and is expected to sustain this pattern throughout the forecast time frame due to the increasing applications-based use in these institutions and the increase in research on cancer. The pharmaceutical and biotechnology sector is expected to experience significant market expansion over the forecast time due to an increase in the prevalence of chronic diseases and advances in R&D for the next-generation sequencing market for therapies, oncology and genomics research.

By End-User

North America accounted for a significant portion of the market for next-generation sequencing in 2020, and it is expected to keep its position throughout the forecast timeframe due to advancements in Technology for sequencing platforms and the increase in the use of NGS in the region. However, Asia-Pacific is predicted to experience its highest CAGR of 19.0 per cent from 2021 to 2030 due to the increasing demand for NGS and a rise in public awareness of NGS.

The key players in the global next-generation sequencing market are Agilent Technologies Inc., BGI Group, F. Hoffmann-La Roche AG, Illumina Inc, Precigen Inc., (Intrexon Bioinformatics Germany GmbH), Pacific Biosciences of California, Inc., PerkinElmer, Inc., PierianDx Inc., Qiagen N.V. as well as Thermo Fisher Scientific Inc.

By Region

Asia Pacific region would exhibit the most significant CAGR of 19.00 per cent between 2021 and 2030.

The Benefits for Stakeholders

  • The report provides a thorough review of the future generation sequencing market and forecasts for the future and current trends to identify the potential investment pockets.
  • It offers a quantitative assessment of the market from 2021 to 2030 to allow participants to benefit from the current next-generation sequencing market opportunity.
  • An extensive examination of markets using procedures and services aids in understanding the current trends in the industry.
  • The key players and their plans are studied to gain an understanding of the competitive outlook for the market for next-generation sequencing.
Next Generation Sequencing Market  Report Scope and Segmentation 
 
ATTRIBUTESDETAILS
ESTIMATED YEAR2022
BASE YEAR2021
FORECAST YEAR2030
HISTORICAL YEAR2017-2021
UNITValue (USD Million/Billion)
BY REGIONNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

The Key Market Segments

By Product

  • Consumables
  • Consumables for the Sample Preparation
      • DNA Fragmentation, End-Repair, A-Tailing and Size Select
      • Library Preparation and Target Enrichment
    • Quality Control
  • Other Consumables
    • Platforms
    • HiSeq
    • MiSeq
    • Ion Torrent
    • SOLiD
    • Pacbio Rs II and the Sequel System
    • Other Sequencing Platforms
  • Services
  • Sequencing Services
      • RNA Sequencing
      • Whole Exome Sequencing
      • Whole Genome Sequencing
      • Targeted Sequencing
      • Chip Sequencing
      • De Novo Sequencing
    • Methyl Sequencing
  • Data Management Services
      • NGS Data Analysis Services
      • NGS Data Analysis Software & Workbenches
    • NGS Storage, Management and Cloud Computing Solutions

In Application

  • Diagnostics
  • Biomarkers and cancer
  • Reproductive Health
  • Personalized Medicine
  • Agriculture and Animal Research
  • Other Applications

By Technology

  • Synthesis of Sequencing
  • Ion Semiconductor Sequencing
  • Sequencing through Ligation
  • Pyrosequencing
  • Single-Molecule Real-Time Sequencing
  • Other Technologies

For End Users

  • Academic and Research Centers
  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Clinics
  • Other End Users

Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Spain
    • Poland
    • Russia
    • The Netherlands
    • Norway
    • Czech Republic
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Malaysia
    • Thailand
    • Singapore
    • Australia & New Zealand
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Northern Africa
    • Rest of MEA

The Key Market Player

  • Agilent Technologies, Inc
  • BGI Group
  • F. Hoffmann-La Roche AG
  • Illumina Inc
  • Precigen Inc., (Intrexon Bioinformatics Germany GmbH)
  • Pacific Biosciences of California, Inc
  • PerkinElmer, Inc.
  • PierianDx Inc.
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.

Table of Contents

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porters five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Technological advancements in NGS
3.5.1.2.Surge in applications of NGS
3.5.1.3.Increase in partnerships and collaborations strategies
3.5.1.4.Increase in demand for genome mapping programs

3.5.2.Restraint

3.5.2.1.Standardization concerns over NGS-based diagnostics
3.5.2.2.Lack of skilled professionals
3.5.2.3.Ethical and legal limitations

3.5.3.Opportunity

3.5.3.1.Lucrative opportunities in key market players
3.5.3.2.Surge in demand for Cloud computing, a potential data management service

3.5.4.Impact analysis

3.6.Impact analysis of COVID-19 on the next generation sequencing (NGS) market

CHAPTER 4:NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Consumables

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type

4.2.2.1.Sample preparation consumables

4.2.2.1.1.Market size and forecast, by type

4.2.2.1.1.1.DNA Fragmentation, End Repair, A-Tailing,and Size Selection
4.2.2.1.1.2.Library preparation & target enrichment
4.2.2.1.1.3.Quality Control

4.2.2.2.Other Consumables

4.2.2.2.1.Market size and forecast

4.2.3.Market size and forecast, by region
4.2.4.Market analysis by country

4.3.Platforms

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type

4.3.2.1.HiSeq series

4.3.2.1.1.Market size and forecast

4.3.2.2.MiSeq series

4.3.2.2.1.Market size and forecast

4.3.2.3.ION Torrent

4.3.2.3.1.Market size and forecast

4.3.2.4.SOLiD

4.3.2.4.1.Market size and forecast

4.3.2.5.Pacbio Rs II and Sequel systems

4.3.2.5.1.Market size and forecast

4.3.2.6.Other Sequencing Platforms

4.3.2.6.1.Market size and forecast

4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country

4.4.Services

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type

4.4.2.1.Sequencing Services

4.4.2.1.1.Market size and forecast, by type

4.4.2.1.1.1.RNA Sequencing
4.4.2.1.1.2.Whole exome sequencing
4.4.2.1.1.3.Whole genome sequencing
4.4.2.1.1.4.Targeted sequencing
4.4.2.1.1.5.Chip sequencing
4.4.2.1.1.6.De Novo sequencing
4.4.2.1.1.7.Methyl sequencing

4.4.2.2.Data management services

4.4.2.2.1.Market size and forecast, by type

4.4.2.2.1.1.NGS Data Analysis Services
4.4.2.2.1.2.NGS data analysis software & workbenches
4.4.2.2.1.3.NGS storage, management, and cloudcomputing solutions

4.4.3.Market size and forecast, by region
4.4.4.Market analysis by country

CHAPTER 5:NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION

5.1.Overview
5.2.Market size and forecast
5.3.Biomarkers and cancer

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Diagnostics

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Reproductive health

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Personalized medicine

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

5.7.Agriculture and animal research

5.7.1.Market size and forecast, by region
5.7.2.Market analysis by country

5.8.Other applications

5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country

CHAPTER 6:NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY

6.1.Overview
6.2.Market size and forecast
6.3.Sequencing by synthesis (SBS)

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Ion semiconductor sequencing (IOS)

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

6.5.Sequencing by Ligation (SBL)

6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country

6.6.Pyrosequencing

6.6.1.Market size and forecast, by region
6.6.2.Market analysis, by country

6.7.Single-molecule-real-time sequencing (SMRT)

6.7.1.Market size and forecast, by region
6.7.2.Market analysis, by country

6.8.Other technologies

6.8.1.Market size and forecast, by region
6.8.2.Market analysis, by country

CHAPTER 7:NEXT-GENERATION SEQUENCING MARKET, BY END USER

7.1.Overview
7.2.Market size and forecast
7.3.Academic & clinical research centers

7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country

7.4.Pharmaceutical & biotechnology companies

7.4.1.Market size and forecast, by region
7.4.2.Market analysis, by country

7.5.Hospitals & clinics

7.5.1.Market size and forecast, by region
7.5.2.Market analysis, by country

7.6.Other end users

7.6.1.Market size and forecast, by region
7.6.2.Market analysis, by country

CHAPTER 8:NEXT-GENERATION SEQUENCING MARKET, BY REGION

8.1.Overview

8.1.1.Market size and forecast

8.2.North America

8.2.1.Key market trends and opportunities
8.2.2.North America next-generation sequencing market, by country

8.2.2.1.U.S.

8.2.2.1.1.U.S. next-generation sequencing market, by product
8.2.2.1.2.U.S. next-generation sequencing market, by application
8.2.2.1.3.U.S. next-generation sequencing market, by technology
8.2.2.1.4.U.S. next-generation sequencing market, by end user

8.2.2.2.Canada

8.2.2.2.1.Canada next-generation sequencing market, by product
8.2.2.2.2.Canada next-generation sequencing market,by application
8.2.2.2.3.Canada next-generation sequencing market,by technology
8.2.2.2.4.Canada next-generation sequencing market, by end user

8.2.2.3.Mexico

8.2.2.3.1.Mexico next-generation sequencing market, by product
8.2.2.3.2.Mexico next-generation sequencing market,by application
8.2.2.3.3.Mexico next-generation sequencing market,by technology
8.2.2.3.4.Mexico next-generation sequencing market, by end user

8.2.3.North America next-generation sequencing market, by product
8.2.4.North America next-generation sequencing market, by application
8.2.5.North America next-generation sequencing market, by technology
8.2.6.North America next-generation sequencing market, by end user

8.3.Europe

8.3.1.Key market trends and opportunities
8.3.2.Europe next-generation sequencing market, by country

8.3.2.1.Germany next-generation sequencing market, by product
8.3.2.2.Germany

8.3.2.2.1.Germany next-generation sequencing market, by application
8.3.2.2.2.Germany next-generation sequencing market, by technology
8.3.2.2.3.Germany next-generation sequencing market, by end user

8.3.2.3.France

8.3.2.3.1.France next-generation sequencing market, by product
8.3.2.3.2.France next-generation sequencing market, by application
8.3.2.3.3.France next-generation sequencing market, by technology
8.3.2.3.4.France next-generation sequencing market, by end user

8.3.2.4.Italy

8.3.2.4.1.Italy next-generation sequencing market, by product
8.3.2.4.2.Italy next-generation sequencing market, by application
8.3.2.4.3.Italy next-generation sequencing market, by technology
8.3.2.4.4.Italy next-generation sequencing market, by end user

8.3.2.5.UK

8.3.2.5.1.UK next-generation sequencing market, by product
8.3.2.5.2.UK next-generation sequencing market, by application
8.3.2.5.3.UK next-generation sequencing market, by technology
8.3.2.5.4.UK next-generation sequencing market, by end user

8.3.2.6.Spain

8.3.2.6.1.Spain next-generation sequencing market, by product
8.3.2.6.2.Spain next-generation sequencing market, by application
8.3.2.6.3.Spain next-generation sequencing market, by technology
8.3.2.6.4.Spain next-generation sequencing market, by end user

8.3.2.7.Rest of Europe

8.3.2.7.1.Rest of Europe next-generation sequencing market,by product
8.3.2.7.2.Rest of Europe next-generation sequencing market,by application
8.3.2.7.3.Rest of Europe next-generation sequencing market,by technology
8.3.2.7.4.Rest of Europe next-generation sequencing market,by end user

8.3.3.Europe next-generation sequencing market, by product
8.3.4.Europe next-generation sequencing market, by application
8.3.5.Europe next-generation sequencing market, by technology
8.3.6.Europe next-generation sequencing market, by end user

8.4.Asia-Pacific

8.4.1.Key market trends and opportunities
8.4.2.Asia-Pacific next-generation sequencing market, by country

8.4.2.1.Australia

8.4.2.1.1.Australia next-generation sequencing market, by product
8.4.2.1.2.Australia next-generation sequencing market,by application
8.4.2.1.3.Australia next-generation sequencing market,by technology
8.4.2.1.4.Australia next-generation sequencing market, by end user

8.4.2.2.Japan

8.4.2.2.1.Japan next-generation sequencing market, by product
8.4.2.2.2.Japan next-generation sequencing market, by application
8.4.2.2.3.Japan next-generation sequencing market, by technology
8.4.2.2.4.Japan next-generation sequencing market, by end user

8.4.2.3.India

8.4.2.3.1.India next-generation sequencing market, by product
8.4.2.3.2.India next-generation sequencing market, by application
8.4.2.3.3.India next-generation sequencing market, by technology
8.4.2.3.4.India next-generation sequencing market, by end user

8.4.2.4.China

8.4.2.4.1.China next-generation sequencing market, by product
8.4.2.4.2.China next-generation sequencing market, by application
8.4.2.4.3.China next-generation sequencing market, by technology
8.4.2.4.4.China next-generation sequencing market, by end user

8.4.2.5.South Korea

8.4.2.5.1.South Korea next-generation sequencing market,by product
8.4.2.5.2.South Korea next-generation sequencing market,by application
8.4.2.5.3.South Korea next-generation sequencing market,by technology
8.4.2.5.4.South Korea next-generation sequencing market,by end user

8.4.2.6.Taiwan

8.4.2.6.1.Taiwan next-generation sequencing market, by product
8.4.2.6.2.Taiwan next-generation sequencing market,by application
8.4.2.6.3.Taiwan next-generation sequencing market,by technology
8.4.2.6.4.Taiwan next-generation sequencing market, by end user

8.4.2.7.Rest of Asia-Pacific

8.4.2.7.1.Rest of Asia-Pacific next-generation sequencing market,by product
8.4.2.7.2.Rest of Asia-Pacific next-generation sequencing market,by application
8.4.2.7.3.Rest of Asia-Pacific next-generation sequencing market,by technology
8.4.2.7.4.Rest of Asia-Pacific next-generation sequencing market,by end user

8.4.3.Asia-Pacific next-generation sequencing market, by product
8.4.4.Asia-Pacific next-generation sequencing market, by application
8.4.5.Asia-Pacific next-generation sequencing market, by technology
8.4.6.Asia-Pacific next-generation sequencing market, by end user

8.5.LAMEA

8.5.1.Key market trends and opportunities
8.5.2.LAMEA next-generation sequencing market, by country

8.5.2.1.Brazil

8.5.2.1.1.Brazil next-generation sequencing market, by product
8.5.2.1.2.Brazil next-generation sequencing market, by application
8.5.2.1.3.Brazil next-generation sequencing market, by technology
8.5.2.1.4.Brazil next-generation sequencing market, by end user

8.5.2.2.Turkey

8.5.2.2.1.Turkey next-generation sequencing market, by product
8.5.2.2.2.Turkey next-generation sequencing market, by application
8.5.2.2.3.Turkey next-generation sequencing market, by technology
8.5.2.2.4.Turkey next-generation sequencing market, by end user

8.5.2.3.Saudi Arabia

8.5.2.3.1.Saudi Arabia next-generation sequencing market,by product
8.5.2.3.2.Saudi Arabia next-generation sequencing market,by application
8.5.2.3.3.Saudi Arabia next-generation sequencing market,by technology
8.5.2.3.4.Saudi Arabia next-generation sequencing market,by end user

8.5.2.4.South Africa

8.5.2.4.1.South Africa next-generation sequencing market,by product
8.5.2.4.2.South Africa next-generation sequencing market,by application
8.5.2.4.3.South Africa next-generation sequencing market,by technology
8.5.2.4.4.South Africa next-generation sequencing market,by end user

8.5.2.5.Rest of LAMEA

8.5.2.5.1.Rest of LAMEA next-generation sequencing market,by product
8.5.2.5.2.Rest of LAMEA next-generation sequencing market,by application
8.5.2.5.3.Rest of LAMEA next-generation sequencing market,by technology
8.5.2.5.4.Rest of LAMEA next-generation sequencing market,by end user

8.5.3.LAMEA next-generation sequencing market, by product
8.5.4.LAMEA next-generation sequencing market, by application
8.5.5.LAMEA next-generation sequencing market, by technology
8.5.6.LAMEA next-generation sequencing market, by end user

CHAPTER 9:COMPANY PROFILES

9.1.AGILENT TECHNOLOGIES, INC.

9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance
9.1.6.Key strategic moves and developments

9.2.BGI GROUP

9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Key strategic moves and developments

9.3.F. HOFFMANN-LA ROCHE AG

9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.3.6.Key strategic moves and developments

9.4.ILLUMINA INC.

9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments

9.5.PRECIGEN INC., (INTREXON BIOINFORMATICS GERMANY GMBH)

9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance

9.6.PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.6.6.Key strategic moves and developments

9.7.PERKINELMER, INC.

9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance
9.7.6.Key strategic moves and developments

9.8.PIERIANDX INC.

9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Key strategic moves and developments

9.9.QIAGEN N.V.

9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.9.6.Key strategic moves and developments

9.10.THERMO FISHER SCIENTIFIC INC.

9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
9.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 02.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR CONSUMABLES, BY TYPE 20202030 ($MILLION)
TABLE 03.SAMPLE PREPARATION CONSUMABLES MARKET REVENUE, BY TYPE, 20202030 ($MILLION)
TABLE 04.DNA FRAGMENTATION, END REPAIR, A-TAILING & SIZE SELECTION: KEY PRODUCTS
TABLE 05.LIBRARY PREPARATION & TARGET ENRICHMENT: KEY PRODUCTS
TABLE 06.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR CONSUMABLES, BY REGION
20202030($MILLION)
TABLE 07.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR PLATFORMS, BY TYPE 20202030 ($MILLION)
TABLE 08.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR PLATFORM, BY REGION
20202030($MILLION)
TABLE 09.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR SERVICES, BY TYPE 20202030 ($MILLION)
TABLE 10.SEQUENCING SERVICES MARKET REVENUE, BY TYPE, 20202030 ($MILLION)
TABLE 11.SEQUENCING SERVICES MARKET REVENUE, BY TYPE, 20202030 ($MILLION)
TABLE 12.NGS DATA ANALYSIS SOFTWARE & WORKBENCHES: KEY PRODUCTS
TABLE 13.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR SERVICES, BY REGION 20202030($MILLION)
TABLE 14.GLOBAL NEXT-GENERATION SEQUENCING MARKET REVENUE, BY APPLICATION, 2018-2026 ($MILLION)
TABLE 15.NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR
BIOMARKERS AND CANCER, BY REGION 20202030($MILLION)
TABLE 16.NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR
DIAGNOSTICS, BY REGION 20202030 ($MILLION)
TABLE 17.NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR REPRODUCTIVE HEALTH, BY REGION 20202030($MILLION)
TABLE 18.NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR PERSONALIZED MEDICINE, BY REGION 20202030 ($MILLION)
TABLE 19.NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR
AGRICULTURE AND ANIMAL RESEARCH, BY REGION 20202030($MILLION)
TABLE 20.NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR
OTHER APPLICATIONS, BY REGION 20202030 ($MILLION)
TABLE 21.GLOBAL NEXT-GENERATION SEQUENCING MARKET REVENUE, BY TECHNOLOGY, 2018-2026 ($MILLION)
TABLE 22.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR SEQUENCING BY SYNTHESIS, BY REGION
20202030 ($MILLION)
TABLE 23.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR ION SEMICONDUCTOR SEQUENCING,
BY REGION 20202030 ($MILLION)
TABLE 24.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR SEQUENCING BY LIGATION, BY REGION
20202030 ($MILLION)
TABLE 25.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR PYROSEQUENCING, BY REGION 20202030 ($MILLION)
TABLE 26.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR SINGLE-MOLECULE-REAL-TIME SEQUENCING,
BY REGION 20202030($MILLION)
TABLE 27.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR OTHER APPLICATIONS, BY REGION
20202030 ($MILLION)
TABLE 28.GLOBAL NEXT-GENERATION SEQUENCING MARKET REVENUE, BY END USER, 20202030 ($MILLION)
TABLE 29.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR ACADEMIC & CLINICAL RESEARCH CENTERS,
BY REGION 20202030 ($MILLION)
TABLE 30.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 20202030 ($MILLION)
TABLE 31.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR HOSPITALS & CLINICS, BY REGION,
20202030 ($MILLION)
TABLE 32.NEXT-GENERATION SEQUENCING MARKET REVENUE FOR OTHER END USERS, BY REGION,
20202030 ($MILLION)
TABLE 33.NEXT-GENERATION SEQUENCING MARKET REVENUE, BY REGION, 20202030 ($MILLION)
TABLE 34.NORTH AMERICA NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 20202030 ($MILLION)
TABLE 35.U.S. NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 20202030 ($MILLION)
TABLE 36.U.S. NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 20202030 ($MILLION)
TABLE 37.U.S. NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 20202030 ($MILLION)
TABLE 38.U.S. NEXT-GENERATION SEQUENCING MARKET, BY END USER, 20202030 ($MILLION)
TABLE 39.CANADA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 20202030 ($MILLION)
TABLE 40.CANADA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 20202030 ($MILLION)
TABLE 41.CANADA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 20202030 ($MILLION)
TABLE 42.CANADA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 20202030 ($MILLION)
TABLE 43.MEXICO NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 20202030 ($MILLION)
TABLE 44.MEXICO NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 20202030 ($MILLION)
TABLE 45.MEXICO NEXT-GENERA

Major Companies

  • Agilent Technologies, Inc
  • BGI Group
  • F. Hoffmann-La Roche AG
  • Illumina Inc
  • Precigen Inc., (Intrexon Bioinformatics Germany GmbH)
  • Pacific Biosciences of California, Inc
  • PerkinElmer, Inc.
  • PierianDx Inc.
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.

Major Segmentation

by Product

  • Consumables
  • Consumables for the Sample Preparation
      • DNA Fragmentation, End-Repair, A-Tailing and Size Select
      • Library Preparation and Target Enrichment
    • Quality Control
  • Other Consumables
    • Platforms
    • HiSeq
    • MiSeq
    • Ion Torrent
    • SOLiD
    • Pacbio Rs II and the Sequel System
    • Other Sequencing Platforms
  • Services
  • Sequencing Services
      • RNA Sequencing
      • Whole Exome Sequencing
      • Whole Genome Sequencing
      • Targeted Sequencing
      • Chip Sequencing
      • De Novo Sequencing
    • Methyl Sequencing
  • Data Management Services
      • NGS Data Analysis Services
      • NGS Data Analysis Software & Workbenches
    • NGS Storage, Management and Cloud Computing Solutions

In Application

  • Diagnostics
  • Biomarkers and cancer
  • Reproductive Health
  • Personalized Medicine
  • Agriculture and Animal Research
  • Other Applications

by Technology

  • Synthesis of Sequencing
  • Ion Semiconductor Sequencing
  • Sequencing through Ligation
  • Pyrosequencing
  • Single-Molecule Real-Time Sequencing
  • Other Technologies

For End Users

  • Academic and Research Centers
  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Clinics
  • Other End Users

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF